Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT01616303
Title A Controlled Study of the Effectiveness of Oregovomab (Antibody) Plus Chemotherapy in Advanced Ovarian Cancer
Recruitment Completed
Gender female
Phase Phase II
Variant Requirements No
Sponsors Quest PharmaTech Inc.
Indications

ovarian cancer

Therapies

Carboplatin + Oregovomab + Paclitaxel

Carboplatin + Paclitaxel

Age Groups: adult
Covered Countries USA


No variant requirements are available.